Bioresorbable Coronary Scaffold Articles & Analysis: Older
14 news found
“The funding we have secured will allow REVA to move forward with our pivotal clinical trial to support FDA approval of our MOTIV peripheral vascular scaffold as well as to obtain FDA clearance of our TyroSphere bioresorbable embolic bead ...
Yoshinobu Onuma, MD, PhD is a leading expert in the field of bioresorbable scaffolds. He also has extensive expertise in quantative coronary angiography (2-dimensional, 3-dimensional and bifurcation-dedicated), intravascular imaging, Syntax Score and metallic stents. ...
Following the successful completion of the R&D project in 30th September 2016 (supported by a Smart award from the Innovate UK (TSB), Arterius has recently been awarded further funding from the Biomedical Catalyst-Early Stage programme to conduct the In-vitro and In-vivo GLP Evaluation of the Novel Bioresorbable Coronary Scaffolds; ...
Arterius are delighted to be working with Professor Patrick Serruys of Erasmus Medical Centre (Netherlands) and Cardialysis. Professor Serruys presented a talk entitled “Bench testing evaluation of a novel fully drug-eluting BRS” at EuroPCR on 19th May 2016. The talk was part of the “BRS: Evolving Technologies and Applications” session, also featuring presentations ...
ArterioSorb has been shown to show decreased acute thrombus formation compared to thicker strut bioresorbable scaffolds (BRS) in an in-vitro model. Shengjie Lu PhD, of the National Heart Research Institute and National Heart Centre Singapore, presented a moderated poster at TCT 2017 in Denver, showing the impact of BRS strut thickness on the formation of ...
(“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the presentation of the 6- month clinical outcomes data from a post market study of the Company’s MOTIV Below The Knee (BTK) scaffold. ...
The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United States. ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance. ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. ...
– January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. ...
The PROSPECT II study demonstrated the ability of near-infrared spectroscopy (NIRS) imaging plus intravascular ultrasound (IVUS) to identify coronary plaques responsible for future coronary events. The randomized substudy PROSPECT ABSORB, which was simultaneously published in the Journal of the American College of Cardiology (JACC), showed treatment of high-risk ...